Original Research
Published on 14 Jun 2021
EGFR-Mutated Squamous Cell Lung Cancer and Its Association With Outcomes
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2021.680804
- 21,156 views
- 50 citations
113 articles related to "Egfr Mutant"
Articles
Original Research
Published on 10 Sep 2020
Metformin Overcomes Acquired Resistance to EGFR TKIs in EGFR-Mutant Lung Cancer via AMPK/ERK/NF-ÎşB Signaling Pathway
in Cancer Molecular Targets and Therapeutics
Frontiers in Oncology
doi 10.3389/fonc.2020.01605
- 7,916 views
- 35 citations
Review
Published on 03 Jul 2018
Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2018.00208
- 25,036 views
- 85 citations
Case Report
Published on 25 Nov 2022
Case report: an initially unresectable stage III pulmonary sarcomatoid carcinoma qith EGFR mutation achieving pathological complete response following neoadjuvant therapy with osimertinib plus chemotherapy
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.1033322
- 3,356 views
- 3 citations
Review
Published on 22 Jul 2022
Immunotherapy for EGFR-mutant advanced non-small-cell lung cancer: Current status, possible mechanisms and application prospects
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2022.940288
- 22,083 views
- 30 citations
Original Research
Published on 24 Sep 2021
Identification of a Gene Signature Closely Related to Immunosuppressive Tumour Microenvironment Predicting Prognosis of Patients in EGFR Mutant Lung Adenocarcinoma
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2021.732841
- 3,327 views
- 3 citations
Review
Published on 14 Jul 2020
Targeting Immunometabolism Mediated by CD73 Pathway in EGFR-Mutated Non-small Cell Lung Cancer: A New Hope for Overcoming Immune Resistance
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2020.01479
- 13,215 views
- 45 citations
Original Research
Published on 16 Feb 2023
Targeting tumor-associated macrophages with STING agonism improves the antitumor efficacy of osimertinib in a mouse model of EGFR-mutant lung cancer
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2023.1077203
- 8,614 views
- 33 citations
Original Research
Published on 20 May 2025
ARID1A deficiency attenuates the response to EGFR-TKI treatment in lung adenocarcinoma
in Pharmacogenetics and Pharmacogenomics
Frontiers in Pharmacology
doi 10.3389/fphar.2025.1582005
- 2,894 views
- 1 citation
Original Research
Published on 14 Oct 2025
Integrative modeling of malignant epithelial programs in EGFR-mutant LUAD via single-cell transcriptomics and multi-algorithm machine learning
in Molecular Innate Immunity
Frontiers in Immunology
doi 10.3389/fimmu.2025.1661679
- 2,774 views
- 1 citation
Original Research
Published on 31 Jan 2020
Enhanced Expression of CD47 Is Associated With Off-Target Resistance to Tyrosine Kinase Inhibitor Gefitinib in NSCLC
in Cancer Immunity and Immunotherapy
Frontiers in Immunology
doi 10.3389/fimmu.2019.03135
- 13,182 views
- 67 citations
Original Research
Published on 19 Jan 2023
Feiyiliu Mixture sensitizes EGFRDel19/T790M/C797S mutant non-small cell lung cancer to osimertinib by attenuating the PRC1/Wnt/EGFR pathway
in Pharmacology of Anti-Cancer Drugs
Frontiers in Pharmacology
doi 10.3389/fphar.2023.1093017
- 6,224 views
- 13 citations
Systematic Review
Published on 12 Apr 2021
Adjuvant EGFR-TKIs for Patients With Resected EGFR-Mutant Non-Small Cell Lung Cancer: A Meta-Analysis of 1,283 Patients
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2021.629394
- 8,408 views
- 28 citations
Review
Published on 25 May 2021
Immunotherapy in Treating EGFR-Mutant Lung Cancer: Current Challenges and New Strategies
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2021.635007
- 50,297 views
- 144 citations
Original Research
Published on 23 Jan 2023
MMP11 is associated with the immune response and immune microenvironment in EGFR-mutant lung adenocarcinoma
in Cancer Immunity and Immunotherapy
Frontiers in Oncology
doi 10.3389/fonc.2023.1055122
- 4,475 views
- 14 citations
Mini Review
Published on 21 Sep 2022
Minimal residual disease in EGFR-mutant non-small-cell lung cancer
in Thoracic Oncology
Frontiers in Oncology
doi 10.3389/fonc.2022.1002714
- 5,107 views
- 4 citations